T2 Biosystems to Report Third Quarter 2021 Financial Results on November 4, 2021
T2 Biosystems, Inc. (NASDAQ:TTOO) will announce its third-quarter 2021 financial results on November 4, 2021, after the market closes. A conference call will follow at 4:30 p.m. ET to discuss the results. Interested investors can access the call through a live and archived webcast via the company's website or by dialing in directly. T2 Biosystems specializes in rapid detection of sepsis-causing pathogens, aiming to enhance patient care while reducing costs. Their product lineup includes instruments and panels utilizing proprietary T2 Magnetic Resonance technology.
- Third quarter financial results announcement set for November 4, 2021.
- Company focuses on improving patient care and reducing healthcare costs.
- None.
LEXINGTON, Mass., Oct. 22, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the third quarter of 2021 after market close on Thursday, November 4, 2021. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. The call will also be available by dialing 1-844-825-9789 (U.S.) or 1-412-317-5180 (International) five to ten minutes prior to the start time.
About T2 Biosystems:
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance™ Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.
Media Contact:
Gina Kent, Vault Communications
gkent@vaultcommunications.com
610-455-2763
Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406
FAQ
When will T2 Biosystems release its third-quarter 2021 financial results?
What time is the T2 Biosystems conference call for the financial results?
How can I access the T2 Biosystems conference call?
What is T2 Biosystems known for?
